ライフサイエンスコーパス: hemoglobinuria

1 pe of the human disease paroxysmal nocturnal hemoglobinuria.

2 ntage of blood cells in paroxysmal nocturnal hemoglobinuria.

3 ted HTRs, exemplified by rapid clearance and hemoglobinuria.

4 number of patients with paroxysmal nocturnal hemoglobinuria.

5 ment, leading to intravascular hemolysis and hemoglobinuria.

6 ells from patients with paroxysmal nocturnal hemoglobinuria.

7 for reported cases of hemoglobinemia and/or hemoglobinuria.

8 s from the pounding of feet on pavement, and hemoglobinuria.

9 inance in patients with paroxysmal nocturnal hemoglobinuria.

10 ells from patients with paroxysmal nocturnal hemoglobinuria.

11 carried a diagnosis of paroxysmal nocturnal hemoglobinuria, a relative contraindication for liver tr

12 phocyte pool; in AA and paroxysmal nocturnal hemoglobinuria, a seemingly random overrepresentation of

13 has been recognized as paroxysmal nocturnal hemoglobinuria, an acquired clonal disorder associated w

14 atment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

15 bin in the plasma and prevented SRBC-induced hemoglobinuria and kidney injury.

16 y of complement such as paroxysmal nocturnal hemoglobinuria and other diseases.

17 anti-D-IGIV-associated hemoglobinemia and/or hemoglobinuria and provides pretreatment and posttreatme

18 mice at 14 days had severe pulmonary edema, hemoglobinuria, and glomerulonephritis.

19 protein C5 reduces intravascular hemolysis, hemoglobinuria, and the need for transfusion, with an as

20 th sickle cell disease, paroxysmal nocturnal hemoglobinuria, beta-thalassemia major, or thalassemia i

21 on the hypothesis that paroxysmal nocturnal hemoglobinuria cells are more sensitive to APC-activated

22 and those with expanded paroxysmal nocturnal hemoglobinuria clones showed more skewed VB repertoires.

23 that FB28.4.2 protected paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hem

24 ents who experienced acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for

25 DIC associated with acute hemoglobinemia or hemoglobinuria following anti-D IGIV administration for

26 received 15 reports of hemoglobinemia and/or hemoglobinuria following anti-D IGIV administration that

27 ells from patients with paroxysmal nocturnal hemoglobinuria in either the acidified serum or "sugar w

28 emolysis suffering from paroxysmal nocturnal hemoglobinuria in which the acquired mutation in the PIG

29 emolytic states such as paroxysmal nocturnal hemoglobinuria, in which plasma hemoglobin concentration

30 Paroxysmal nocturnal hemoglobinuria is an acquired hematopoietic stem cell (H

31 Paroxysmal nocturnal hemoglobinuria is frequently associated with aplastic an

32 tic, defining defect in paroxysmal nocturnal hemoglobinuria is the somatic mutation of the PIG-A gene

33 hanism responsible for hemoglobinemia and/or hemoglobinuria is unexplained.

34 ue for the diagnosis of paroxysmal nocturnal hemoglobinuria; it is clearly more specific, more quanti

35 plasms, acute leukemia, paroxysmal nocturnal hemoglobinuria, mast cell disease, myelodysplastic syndr

36 -A genes in humans with paroxysmal nocturnal hemoglobinuria may be subject to comparable pathophysiol

37 , anemia, elevated liver function tests, and hemoglobinuria-may be especially severe in asplenic or i

38 diated disease model of paroxysmal nocturnal hemoglobinuria, mini-FH largely outperformed FH and indi

39 lonal disorder, such as paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, or leukemia.

40 e, cold agglutinin syndrome, paroxysmal cold hemoglobinuria, or autoimmune hemolytic anemia secondary

41 plement regulation on a paroxysmal nocturnal hemoglobinuria patient's erythrocytes.

42 with the PIG-A mutant (paroxysmal nocturnal hemoglobinuria) phenotype at a median frequency (f) of a

43 amined 19 patients with paroxysmal nocturnal hemoglobinuria (PNH) (18 with active disease and 1 spont

44 (mAb) for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndr

45 ls to disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndr

46 revent complications of paroxysmal nocturnal hemoglobinuria (PNH) and improve quality of life and ove

47 (-) cells in 2 cases of paroxysmal nocturnal hemoglobinuria (PNH) and some myeloproliferative neoplas

48 the natural history of paroxysmal nocturnal hemoglobinuria (PNH) and to review new therapeutic strat

49 AA and paroxysmal nocturnal hemoglobinuria (PNH) are related clinically, and glycoph

50 Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of t

51 Cy arm had evidence of paroxysmal nocturnal hemoglobinuria (PNH) at diagnosis, with no substantial c

52 the genetic basis of a paroxysmal nocturnal hemoglobinuria (PNH) case without somatic mutations in P

53 Paroxysmal nocturnal hemoglobinuria (PNH) cells are partially (type II) or co

54 Paroxysmal nocturnal hemoglobinuria (PNH) cells are susceptible to hemolysis

55 has been proposed that paroxysmal nocturnal hemoglobinuria (PNH) cells may proliferate through their

56 cells in patients with paroxysmal nocturnal hemoglobinuria (PNH) comprise a mixture of residual norm

57 cells in patients with paroxysmal nocturnal hemoglobinuria (PNH) comprise variable mixtures of norma

58 Paroxysmal nocturnal hemoglobinuria (PNH) develops in patients who have had a

59 complement pathway, of paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes in human serum.

60 netic defect underlying paroxysmal nocturnal hemoglobinuria (PNH) has been shown to reside in PIGA, a

61 Patients with paroxysmal nocturnal hemoglobinuria (PNH) have blood cells deficient in glyco

62 Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell

63 Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell

64 Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal stem cell disorder caus

65 Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal stem cell disorder char

66 Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder of hematopoietic stem

67 Paroxysmal nocturnal hemoglobinuria (PNH) is a nonmalignant clonal disease of

68 Paroxysmal nocturnal hemoglobinuria (PNH) is a rare bone marrow failure disor

69 Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal blood disorder tha

70 Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired blood disease with d

71 Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder of t

72 Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic

73 Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem-c

74 Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia cha

75 Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia res

76 Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired stem cell disorder c

77 Paroxysmal nocturnal hemoglobinuria (PNH) is caused by phosphatidylinositol g

78 Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-medi

79 Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-medi

80 Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular h

81 Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by the presence in

82 he clinical hallmark of paroxysmal nocturnal hemoglobinuria (PNH) is chronic intravascular hemolysis

83 The syndrome paroxysmal nocturnal hemoglobinuria (PNH) is intimately related to aplastic a

84 marrow failure (BMF) in paroxysmal nocturnal hemoglobinuria (PNH) is not yet known.

85 distinctive feature of paroxysmal nocturnal hemoglobinuria (PNH) is that in each patient glycosylpho

86 feared complication of paroxysmal nocturnal hemoglobinuria (PNH) is thrombosis.

87 Patients with paroxysmal nocturnal hemoglobinuria (PNH) lack GPI proteins on the surface of

88 myelodysplasia (MDS) or paroxysmal nocturnal hemoglobinuria (PNH) occurring as a late complication of

89 complement activity in paroxysmal nocturnal hemoglobinuria (PNH) patients on eculizumab treatment.

90 f 35 AA, 37 MDS, and 21 paroxysmal nocturnal hemoglobinuria (PNH) patients, in whom specific CDR3 seq

91 rom the erythrocytes of paroxysmal nocturnal hemoglobinuria (PNH) patients, who suffer from complemen

92 A 10-year-old girl with paroxysmal nocturnal hemoglobinuria (PNH) received an infusion of syngeneic b

93 Paroxysmal nocturnal hemoglobinuria (PNH) results from somatic mutations in t

94 ytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) undergoing eculizumab treatment, wh

95 eport on a patient with paroxysmal nocturnal hemoglobinuria (PNH) who does not have a mutation of PIG

96 ets of 54 patients with paroxysmal nocturnal hemoglobinuria (PNH) with antibodies to glycosylphosphat

97 tient to be treated for paroxysmal nocturnal hemoglobinuria (PNH) with syngeneic bone marrow transpla

98 ement-mediated lysis in paroxysmal nocturnal hemoglobinuria (PNH), a disease that manifests after clo

99 clinical management of paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening hemato

100 In paroxysmal nocturnal hemoglobinuria (PNH), acquired somatic mutations in the

101 In paroxysmal nocturnal hemoglobinuria (PNH), an acquired mutation of the PIGA g

102 h aplastic anemia (AA), paroxysmal nocturnal hemoglobinuria (PNH), and myelodysplasia (MDS).

103 g aplastic anemia (AA), paroxysmal nocturnal hemoglobinuria (PNH), and some forms of myelodysplasia (

104 In paroxysmal nocturnal hemoglobinuria (PNH), hematopoietic cells lacking glycos

105 ells from patients with paroxysmal nocturnal hemoglobinuria (PNH), leading to deficiency of GPI-linke

106 rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a defi

107 PCs) from patients with paroxysmal nocturnal hemoglobinuria (PNH).

108 a is a major feature of paroxysmal nocturnal hemoglobinuria (PNH).

109 s a defining feature of paroxysmal nocturnal hemoglobinuria (PNH).

110 erated in patients with paroxysmal nocturnal hemoglobinuria (PNH).

111 c disorders, especially paroxysmal nocturnal hemoglobinuria (PNH).

112 ytes from patients with paroxysmal nocturnal hemoglobinuria (PNH); the authors demonstrate that these

113 cytes that recapitulate paroxysmal nocturnal hemoglobinuria, PspCN enhanced protection of cells by FH

114 Paroxysmal cold hemoglobinuria requires aggressive supportive therapy, g

115 molytic anemias such as paroxysmal nocturnal hemoglobinuria, sickle cell disease, and thalassemia.

116 to complement lysis in paroxysmal nocturnal hemoglobinuria syndrome.

117 molytic anemia syndrome paroxysmal nocturnal hemoglobinuria, the in vivo biology of DAF is still poor

118 Episodes of hemoglobinuria were reduced by 96 percent (P<0.001), and

119 ytes from patients with paroxysmal nocturnal hemoglobinuria, which lack glycosylphosphatidylinositol-

120 , schistocytosis, free hemoglobin in plasma, hemoglobinuria with hemosiderinuria, and platelet activa